期刊文献+

阿立派唑对首发精神分裂症患者事件相关电位P300的影响 被引量:5

Effects of aripiprazole on event-related potential P300 in first episode schizophrenia
下载PDF
导出
摘要 目的探讨阿立派唑对精神分裂症患者P300认知电位的影响。方法 36例使用阿立派唑和23例使用氯氮平治疗的首发精神分裂症患者,在治疗前及治疗12周后用阳性与阴性症状量表(PANSS)判定其疗效,进行事件相关电位P300测定,判定其认知功能。结果治疗12周后,两组患者PANSS总分、阳性症状分、阴性症状分及一般精神病理症状分均明显下降,但组间比较差异无统计学意义(P>0.05);P300认知电位测定显示使用阿立派唑治疗组在治疗后P300认知电位潜伏期缩短,波幅增高,与治疗前及与氯氮平治疗组相比较差异均具有统计学意义(P<0.05)。结论阿立派唑与氯氮平对对精神分裂症的疗效相当,但阿立派唑对精神分裂症患者的认知障碍具有一定的改善作用。 Objective To study the effects of aripiprazole on the event-related potential P300 in first episode schizophrenia patients.Methods All patients with first-episode schizophrenia were divided into two groups treated with aripiprazole(n=36) or clozapine(n=23).Positive and negative symptom scale(PANSS) and P300 were used to evaluate the effects of drugs and cognitive function before and after 12 weeks.Results After 12 weeks treatment,some of the scores in two groups were decreased significantly,including total scores of PANSS,positive symptom,negative symptom and general psychopathology subscales,and there were no significant difference in the two groups(P0.05).The amplitude and the latency of waves P300 were shorter and higher than before treatment in aripiprazole group,and there were significant diference in the two groups(P0.05).Conclusion The effects of aripiprazole and clozapine for schizophrenia are equal.Afipiprazole can improve the cognitive disorder in schizophrenia.
出处 《实用临床医药杂志》 CAS 2011年第13期108-110,共3页 Journal of Clinical Medicine in Practice
关键词 精神分裂症 阿立派唑 事件相关电位 认知功能 schizophrenia aripiprazole event-related potential cognitive function
  • 相关文献

参考文献7

二级参考文献26

  • 1向云.精神分裂症与认知功能障碍[J].中国行为医学科学,2005,14(7):620-622. 被引量:65
  • 2谢红涛,施慎逊.住院抑郁症患者糖尿病患病率调查[J].临床精神医学杂志,2006,16(1):21-23. 被引量:13
  • 3刘文庭,杨云霞,赵涛,王任昌,刘哲宁.阿立派唑对精神分裂症患者认知功能的影响[J].中国行为医学科学,2006,15(6):510-511. 被引量:14
  • 4Ronan OC. Cognitive Impairment in schizhophrenia.Advance in Psychiatry Treatment,2000,6:161-168. 被引量:1
  • 5Garcia-Segura LM, Azcoitia T, DonCarlos LL. Neuroprotection by estradiol.Prog Neurobiol.2001,63(1):29-60. 被引量:1
  • 6[1]Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 ( 1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995 Jul, 274( 1 ) :329 ~ 336 被引量:1
  • 7[2]Fleishhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003, 105 ~ 117 被引量:1
  • 8[3]Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[ 4-( 4-phenyl-1-piperazinyl ) butoxy ]-3, 4-dthydro-2 (1H)-quinolinone derivatives. J Med Chem, 1998 Feb, 41 : 658 ~667 被引量:1
  • 9[4]Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacolgy (Berl), 1999 Sep, 146(2) : 139 ~ 143 被引量:1
  • 10[5]Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropschopharmacolgy, 1999 Jun, 20(6) : 612~627 被引量:1

共引文献642

同被引文献34

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部